9989:HKEXShenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Analysis

Shenzhen Hepalink is trading at HK$4.18, well below its 20‑day (HK$4.72), 50‑day (HK$4.89) and 200‑day (HK$5.39) moving averages, indicating a pronounced bearish technical stance. The RSI of 18.6 places the stock in oversold territory, while a bearish MACD histogram reinforces short‑term downside pressure. Despite this, the DCF fair value of HK$11.43 suggests the equity is fundamentally undervalued, a view supported by a low PE of 13.9 versus the industry average of 27.4 and a sub‑1× PB ratio. The company offers a generous dividend yield of 3.75% but a payout ratio of 96% raises concerns about sustainability amid a debt‑to‑equity ratio exceeding 26 and total debt of HK$3.26 bn. Cash generation remains solid with free cash flow over HK$1.2 bn, yet the recent 4.5% revenue contraction and modest ROE of 3% limit growth momentum. Volatility is high at nearly 25% over the past 30 days, though beta is low (0.28), indicating limited market‑wide risk exposure. The fear‑greed index at 91.07 signals extreme market greed, which could amplify price swings. Overall, the stock sits at a critical support level of HK$4.18 with resistance near HK$5.05, and any breakthrough either way could define the next price trajectory.